AIOS Threatened by Manufacturer-Platform Stack

The real threat is control of the patient funnel, not another telehealth brand. If Eli Lilly and Novo Nordisk decide who gets preferred drug access, pricing, and pharmacy routing, then the winning layer becomes the combined manufacturer plus platform stack. In that setup, AIOS is left selling a low margin service around someone else’s inventory, while larger partners keep the branded front door and the supply relationship.

• LillyDirect launched in January 2024 as a digital path for obesity, migraine, and diabetes patients to reach care support and home delivery of Lilly drugs. That made telehealth part of the manufacturer go to market motion, not just an independent reseller channel.
  4 lilly
• The playbook became more explicit in March 2026, when Hims & Hers announced a Novo Nordisk collaboration to bring Ozempic and Wegovy onto its platform. That is the shape of the threat, a scaled consumer brand handling demand generation and intake, with the manufacturer supplying approved drug access behind it.
  5 hims 6 hims
• AIOS is especially exposed because its UK growth has come from passing branded GLP-1s through at cost, which supports only about 20% gross margins, versus the roughly 65% to 80% gross margins Ro and Hims & Hers historically earned on fulfillment. If preferred partnerships tighten supply or economics, AIOS has less margin cushion than broader telehealth platforms.
  1 sacra 2 sacra

The next phase of obesity telehealth will be decided by who owns distribution rights and patient routing at national scale. AIOS can still grow by aggregating pharmacy capacity across Europe, but the bigger pools of value will sit with platforms that manufacturers actively feed with branded supply, lower cash pay pricing, and default patient traffic.